EGFR and lung cancer: ,5 Although new approaches have emerged during past decades in the treatment of lung cancer patients, including reagents that target epidermal growth factor receptor (EGFR) mutation, alkaline phosphatase (ALK) fusion, and programmed death ligand 1 (PD-L1) immunotherapy,6, 7, 8, 9 the 5-year survival rate of NSCLC remains less than 18%.2